Capital Counsel LLC NY Has $12.70 Million Holdings in Danaher Co. (NYSE:DHR)

Capital Counsel LLC NY decreased its position in Danaher Co. (NYSE:DHR) by 0.4% in the third quarter, HoldingsChannel reports. The firm owned 45,690 shares of the conglomerate’s stock after selling 167 shares during the period. Danaher accounts for about 0.5% of Capital Counsel LLC NY’s investment portfolio, making the stock its 15th biggest holding. Capital Counsel LLC NY’s holdings in Danaher were worth $12,703,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. nVerses Capital LLC acquired a new position in shares of Danaher in the second quarter worth $25,000. CarsonAllaria Wealth Management Ltd. purchased a new position in Danaher in the second quarter valued at about $25,000. MidAtlantic Capital Management Inc. acquired a new position in Danaher in the 3rd quarter worth about $40,000. Darwin Wealth Management LLC purchased a new stake in shares of Danaher during the 3rd quarter worth about $55,000. Finally, MFA Wealth Advisors LLC acquired a new position in Danaher in the second quarter worth approximately $51,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Price Performance

Danaher stock opened at $236.53 on Wednesday. The company has a market capitalization of $170.84 billion, a price-to-earnings ratio of 45.14, a PEG ratio of 4.37 and a beta of 0.85. The stock’s 50 day moving average is $256.66 and its 200-day moving average is $259.81. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher Co. has a 12 month low of $215.68 and a 12 month high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the company posted $2.02 earnings per share. Danaher’s revenue was up 3.1% compared to the same quarter last year. Equities research analysts expect that Danaher Co. will post 7.5 EPS for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio is 20.61%.

Analyst Upgrades and Downgrades

Several research firms have commented on DHR. TD Cowen boosted their target price on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Raymond James decreased their price target on Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. UBS Group lowered their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target for the company in a report on Thursday, October 31st. Finally, Robert W. Baird reduced their target price on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $287.16.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.